Multitude multicolor chromosome banding (mMCB) – a comprehensive one-step multicolor FISH banding methodWeise A.a · Heller A.a · Starke H.a · Mrasek K.a · Kuechler A.a,b · Pool-Zobel B.L.c · Claussen U.a · Liehr T.a
aInstitute of Human Genetics and Anthropology and Departments of bRadiation Oncology, cNutritional Toxicology, Institute of Nutrition, University of Jena, Jena (Germany)
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Multicolor chromosome banding (MCB) using one single chromosome-specific MCB probe set per experiment was previously reported as powerful tool in molecular cytogenetics for the characterization of all kinds of human marker chromosomes. However, a quick analysis of karyotypes with highly complex chromosomal changes was hampered by the problem that up to 24 MCB experiments were necessary for a comprehensive karyotype description. To overcome that limitation the 138 available region-specific microdissection-derived libraries for all human chromosomes were combined to one single probe set, called multitude MCB (mMCB). A typical fluorescence banding pattern along the human karyotype is produced, which can be evaluated either by transforming these profiles into chromosome region-specific pseudo-colors or more reliably by studying the fluorescence profiles. The mMCB probe set has been applied on chromosomes of normal male and female probands, two primary myelodysplastic syndromes and two solid tumor cell lines. Additionally, a cell line of Gorilla gorilla (GGO) studied previously by single chromosome-specific MCB was reevaluated by the mMCB method. All results were in concordance with those obtained in parallel or by other cytogenetic and molecular cytogenetic approaches indicating that mMCB is a powerful multicolor FISH banding tool for fast characterization of complex karyotypes.
© 2003 S. Karger AG, Basel
ATCC: The global bioresource center (http://www.atcc.org/) (2003).
- Chudoba I, Plesch A, Lörch T, Lemke J, Claussen U, Senger G: High resolution multicolor-banding: a new technique for refined FISH analysis of human chromosomes. Cytogenet Cell Genet 84:156–160 (1999).
- Heller A, Starke H, Trifonov V, Rubtsov N, Wedding U, Loncarevic I, Bleck C, Claussen U, Liehr T: A complex translocation event between the two homologues of chromosomes 5 leading to a del(5)(q21q33) as a sole aberration in a case clinically diagnosed as CML: characterization of the aberration by multicolor banding. Int J Oncol 20:1179–1181 (2002).
Heller A, Rubtsov N, Kytölä S, Karamysheva TV, Sablina OV, Degtyareva MM, Starke H, Metzke H, Claussen U, Liehr T: Highly complex karyotypic changes in acute myelogenous leukemia: a case report. Int J Oncol 23:139–143 (2003a).
Heller A, Karst C, Loncarevic I, Gebhart E, Claussen U, Liehr T: Comprehensive molecular cytogenetic analysis confirms and refines breakpoint localization in leukemia. Cancer Genet Cytogenet 146:81–83 (2003b).
- Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP: LNCaP model of human prostatic carcinoma. Cancer Res 43:1809–1818 (1983).
Houge G, Liehr T, Schoumans J, Ness GO, Solland K, Starke H, Claussen U, Stromme P, Akre B, Vermeulen S: Ten years follow up of a boy with a complex chromosomal rearrangement: Going from a >5 to 15-breakpoint CCR. Am J med Genet 118A:235–240 (2003).
- Kuechler A, Weise A, Michel S, Schaeferhenrich A, Pool-Zobel BL, Claussen U, Liehr T: Precise breakpoint characterization of the colon adenocarcinoma cell line HT-29 clone 19A by means of 24-color fluorescence in situ hybridization and multicolor banding. Genes Chrom Cancer 36:207–210 (2003).
Liehr T, Claussen U: Current developments in human molecular cytogenetic techniques. Curr molec Med 2:283–297 (2002).
Liehr T, Heller A, Starke H, Claussen U: FISH banding methods: applications in research and diagnostics. Expert Rev molec Diagn 2:217–225 (2002a).
Liehr T, Heller A, Starke H, Rubtsov N, Trifonov V, Mrasek K, Weise A, Kuechler A, Claussen U: Microdissection based high resolution multicolor banding (MCB) for all 24 human chromosomes. Int J molec Med 9:335–339 (2002b).
- Mrasek K, Heller A, Rubtsov N, Trifonov V, Starke H, Rocchi M, Claussen U, Liehr T: Reconstruction of the female Gorilla gorilla karyotype using 25-color FISH and multicolor banding (MCB). Cytogenet Cell Genet 93:242–248 (2001).
- Mrasek K, Heller A, Rubtsov N, Trifonov V, Starke H, Claussen U, Liehr T: Detailed Hylobates lar karyotype defined by 25-color FISH and multicolor banding. Int J molec Med 12:139–146 (2003).
Schaeferhenrich A, Beyer-Sehlmeyer G, Festag G, Kuechler A, Haag N, Weise A, Liehr T, Claussen U, Marian B, Sendt W, Scheele J, Pool-Zobel BL: Human adenoma cells are highly susceptible to the genotoxic action of 4-hydroxy-2-nonenal. Mutat Res 526:19–32 (2003a).
Schaeferhenrich A, Sendt W, Scheele J, Kuechler A, Liehr T, Claussen U, Rapp A, Greulich KO, Pool-Zobel BL: Putative colon cancer risk factors damage global DNA and TP53 in primary human colon cells isolated from surgical samples. Food chem Toxicol 41:655–664 (2003b).
- Schröck E, du Manoir S, Veldman T, Schoell B, Wienberg J, Ferguson-Smith MA, Ning Y, Ledbetter DH, Bar-Am I, Soenksen D, Garini Y, Ried T: Multicolor spectral karyotyping of human chromosomes. Science 273:494–497 (1996).
Senger G, Chudoba I, Plesch A: Multicolor-FISH – the identification of chromosome aberrations by 24 colors. Bioforum 9:499–503 (1998).
- Soule HD, McGrath CM: A simplified method for passage and long-term growth of human mammary epithelial cells. In Vitro Cell Dev Biol 22:6–12 (1986).
- Speicher MR, Gwyn Ballard S, Ward DC: Karyotyping human chromosomes by combinatorial multi-fluor FISH. Nature Genet 12:368–375 (1996).
Starke H, Raida M, Trifonov V, Clement JH, Loncarevic IF, Heller A, Bleck C, Nietzel A, Rubtsov N, Claussen U, Liehr T: Molecular cytogenetic characterization of an acquired supernumerary minute marker chromosome as sole abnormality in a case clinically diagnosed as Philadelphia negative chronic myelogenous leukemia. Br J Haematol 113:435–438 (2001a).
Starke H, Senger G, Kossakiewicz M, Tittelbach H, Rau D, Rubtsov N, Trifonov V, Heller A, Hartmann I, Claussen U, Liehr T: Maternal insertion of 18q11.2-q12.2 in 18p11.3 of the same chromosome analysed by microdissection and multicolour banding (MCB). Prenat Diag 21:1049–1052 (2001b).
Stumm M, Müsebeck J, Tönnies H, Volleth M, Lemke J, Chudoba I, Wieacker P: Partial trisomy 9p12p21.3 with a normal phenotype. J med Genet 39:141–144 (2002).
- Tönnies H, Stumm M, Wegner RD, Chudoba I, Kalscheuer V, Neitzel H: Comparative genomic hybridization based strategy for the analysis of different chromosome imbalances detected in conventional cytogenetic diagnostics. Cytogenet Cell Genet 93:188–194 (2001).
Verma RS, Babu A: Human chromosomes – manual of basic technologies. (Pergamon Press, New York 1989).
- Weise A, Starke H, Heller A, Tönnies H, Volleth M, Stumm M, Senger G, Nietzel A, Claussen U, Liehr T: Chromosome 2 aberrations in clinical cases characterized by high resolution multicolor banding (MCB) and region specific FISH probes. J med Genet 39:434–439 (2002).
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.